Dovitinib

Drug Profile

Dovitinib

Alternative Names: CHIR-258; Dovitinib lactate; GFKI-258; Growth factor kinase inhibitor 258; TKI 258

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Academic and Community Cancer Research United; Georgetown University; National Cancer Institute (USA); Novartis; University of California, Davis; University of Texas M. D. Anderson Cancer Center; University of Virginia; Yonsei University Health System
  • Class Antineoplastics; Benzimidazoles; Lactates; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Adenocarcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Gastrointestinal stromal tumours; Haematological malignancies; Hepatocellular carcinoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours; Thyroid cancer; Urogenital cancer; Von Hippel-Lindau disease

Most Recent Events

  • 26 Oct 2017 The Hoosier Cancer Research Network and Novartis terminates a phase II trial as funding withdrawn due to slow accrual for Urogenital cancer in USA (NCT01732107)
  • 12 Jun 2017 The MD Anderson Cancer Center & Novartis complete a phase II trial for Prostate cancer (castration-resistant, metastatic) in USA (NCT00831792)
  • 01 Nov 2016 Novartis completes a phase II/III trial in Solid tumours in USA, Denmark, Italy, Japan, Netherlands, Spain, Austria and Belgium (PO) (NCT02116803)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top